
Sign up to save your podcasts
Or


Bloomberg Intelligence Senior Pharmaceutical Analyst Sam Fazeli covers the news that Merck will buy Prometheus Biosciences for about $10.8 billion to bolster its research pipeline and strengthen its portfolio of autoimmune drugs. Irving Fain, CEO of Bowery Farming, discusses disruption in the vertical farming space. Honeycomb CEO Christine Yen talks about new funding for the observability cloud platform. And We Drive to the Close with Doug Ciocca, CEO at Kavar Capital.
Hosts: Carol Massar and Madison Mills. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.
By Bloomberg3.7
376376 ratings
Bloomberg Intelligence Senior Pharmaceutical Analyst Sam Fazeli covers the news that Merck will buy Prometheus Biosciences for about $10.8 billion to bolster its research pipeline and strengthen its portfolio of autoimmune drugs. Irving Fain, CEO of Bowery Farming, discusses disruption in the vertical farming space. Honeycomb CEO Christine Yen talks about new funding for the observability cloud platform. And We Drive to the Close with Doug Ciocca, CEO at Kavar Capital.
Hosts: Carol Massar and Madison Mills. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.

1,713 Listeners

977 Listeners

406 Listeners

1,173 Listeners

2,175 Listeners

970 Listeners

686 Listeners

196 Listeners

1,044 Listeners

1,320 Listeners

65 Listeners

30 Listeners

64 Listeners

4 Listeners

58 Listeners

233 Listeners

230 Listeners

69 Listeners

87 Listeners

80 Listeners

81 Listeners

85 Listeners

403 Listeners

9 Listeners

19 Listeners

14 Listeners

7 Listeners

2 Listeners

119 Listeners

24 Listeners